| 生物活性 |
Ligusticum cycloprolactam is a potent, orally active TLR4/NF-κB inhibitor capable of penetrating the central nervous system, exhibiting anti-inflammatory and neuroprotective activities; it reduces FPR1 expression, inhibits the NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK, and TGF-β signaling pathways, and selectively activates hepatic FXR, while decreasing the production of pro-inflammatory mediators, promoting the secretion of anti-inflammatory cytokines, modulating renal urate transporters, and maintaining gut microbiota composition, and can therefore be used for research on ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated steatotic liver disease. |
体外研究 (In Vitro) |
Ligusticum cycloprolactam (LIGc) (2.5-10 μM; 2 h) 可呈剂量依赖性抑制 LPS (MS-X54539) 诱导的 RAW264.7 小鼠巨噬细胞促炎介质 (NO、TNF-α、IL-1β) 生成,并促进抗炎细胞因子 (IL-4、IL-10) 的分泌。 Ligusticum cycloprolactam (2.5-10 μM; 2 h) 可呈剂量依赖性降低 LPS 诱导的 RAW264.7 小鼠巨噬细胞中促炎蛋白 (CD86、iNOS、COX-2) 的表达,并上调抗炎蛋白 (CD206) 的表达。 Ligusticum cycloprolactam (10 μM; 2 h) 可抑制 LPS 诱导的 RAW264.7 小鼠巨噬细胞中促炎基因 (cd86、Nos2) 的表达。 Ligusticum cycloprolactam (LIGc) (10 μM; 2 h) 可降低 LPS 诱导的原代小鼠小胶质细胞中促炎标记物 CD86 的表达。 Ligusticum cycloprolactam (10 μM; 2 h) 可调节 LPS 刺激的 RAW264.7 小鼠巨噬细胞的转录谱,显著下调促炎性 Fpr1 基因并富集抗炎信号通路。 Ligusticum cycloprolactam (10 μM; 2 h) 可抑制 LPS 诱导的 RAW264.7 小鼠巨噬细胞中 FPR1 蛋白的表达。 Ligusticum cycloprolactam (10 μM; 2 h) 可抑制 LPS 诱导的 RAW264.7 小鼠巨噬细胞及原代小鼠小胶质细胞中 NLRP3 蛋白的表达。 Ligusticum cycloprolactam (10 μM; 2 h) 可通过下调 FPR1/NLRP3 信号轴,在 LPS 刺激的 RAW264.7 小鼠巨噬细胞和原代小鼠小胶质细胞中发挥抗炎作用,而 FPR1 过表达可逆转这些作用。 Ligusticum cycloprolactam (20-80 μM; 36 h) 可通过抑制 TLR4/NF-κB 信号通路、减轻炎症及纤维化反应,改善尿酸 (MS-G49441) 诱导的 NRK-52E 细胞损伤。 Ligusticum cycloprolactam (2.5-40 μM; 24 h) 在浓度不超过 20 μM、作用 24 h 时对 BV2 小胶质细胞无细胞毒性作用,但在 40 μM 浓度下会降低细胞活力。 Ligusticum cycloprolactam (5-20 μM; 1 h) 可剂量依赖性地降低脂多糖诱导的 BV2 小胶质细胞中 NO 的生成,其中 10 μM 时的抑制作用最强。 Ligusticum cycloprolactam (5-20 μM; 1 h) 可剂量依赖性地降低脂多糖诱导的 BV2 小胶质细胞中 TNF-α 和 IL-1β 的分泌。 Ligusticum cycloprolactam (10 μM; 1 h) 可通过降低 IκBα、IKKα+β 和 NF-κB p65 的磷酸化水平,抑制 LPS 诱导的 BV2 小胶质细胞中 NF-κB 通路的激活。 Ligusticum cycloprolactam (10 μM; 1 h) 可保护 HT22 海马神经元细胞免受脂多糖激活的 BV2 小胶质细胞条件培养基诱导的神经毒性,恢复 HT22 细胞活力。 Ligusticum cycloprolactam (10 μM; 1 h) 可通过恢复 Bcl2/Bax 比值并降低 BID 和 CytC 的表达,减轻脂多糖激活的 BV2 小胶质细胞诱导的 HT22 海马神经元细胞凋亡 (apoptosis)。 Ligusticum cycloprolactam (LIGc) 在无细胞分子对接实验中直接结合纯化的 FXR 蛋白。
ELISA Assay
| Cell Line: |
LPS-stimulated RAW264.7 mouse macrophages |
| Concentration: |
2.5; 5; 10 μM |
| Incubation Time: |
2 h |
| Result: |
Dose-dependently inhibited LPS-induced production of NO, TNF-α, and IL-1β. Enhanced secretion of IL-4 and IL-10, with optimal effects observed at 10 μM. All changes were statistically significant compared to the LPS-only group. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated RAW264.7 mouse macrophages |
| Concentration: |
2.5; 5; 10 μM |
| Incubation Time: |
2 h |
| Result: |
Dose-dependently attenuated LPS-induced upregulation of CD86, iNOS, and COX-2 protein expression, while increasing CD206 protein expression, with significant differences compared to the LPS-only group at all tested concentrations. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated RAW264.7 mouse macrophages |
| Concentration: |
10 μM (2 h pretreatment); 100 ng/mL LPS (12 h co-treatment) |
| Incubation Time: |
2 h (pretreatment); 12 h (co-treatment) |
| Result: |
Significantly suppressed LPS-induced FPR1 protein expression, compared to the LPS-only group. |
Western Blot Analysis
| Cell Line: |
NRK-52E cells |
| Concentration: |
20; 40; 80 μM |
| Incubation Time: |
36 h |
| Result: |
Effectively reversed the uric acid-induced upregulation of transcription levels for inflammatory and fibrotic markers such as Nlrp3, IL-1b, Fn1 and Tgfb1. Decreased the levels of KIM-1, NLRP3, IL-1β, VCAM1, FN and α-SMA proteins while enhancing E-cadherin protein expres- sion.
|
ELISA Assay
| Cell Line: |
LPS-stimulated mouse BV2 microglia cells |
| Concentration: |
5; 10; 20 μM |
| Incubation Time: |
1 h |
| Result: |
Significantly attenuated LPS-induced increase in TNF-α and IL-1β secretion at 5, 10, and 20 μM. Exhibited the most potent inhibitory effect on both cytokines at 10 μM. |
Cell Viability Assay
| Cell Line: |
BV2 microglia cells |
| Concentration: |
2.5; 5; 10; 20; 40 μM |
| Incubation Time: |
24 h |
| Result: |
Showed cytotoxic effect on BV2 microglia cells at concentrations up to 20 μM. Reduces cell viability at 40 μM.
|
|
体内研究 (In Vivo) |
Ligusticum cycloprolactam (LIGc) (20 和 60 mg/kg;口服;每日 1 次;连续 4 天) 可通过抑制促炎性小胶质细胞/巨噬细胞活化并调控 FPR1/NLRP3 信号轴,减轻 LPS 诱导的神经炎症小鼠模型中的神经炎症。 Ligusticum cycloprolactam (20 和 60 mg/kg;灌胃;脑缺血再灌注后 1、24、48 小时) 可呈剂量依赖性缩小大脑中动脉栓塞 (tMCAO) 模型小鼠的脑梗死体积并改善其神经功能。 Ligusticum cycloprolactam (20-80 mg/kg;灌胃;每日给药;连续 3 周) 可通过抑制 TLR4/NF-κB 通路降低尿酸水平、减轻肾脏炎症与纤维化,从而改善小鼠高尿酸血症肾病。
| Animal Model: |
Adult male Kunming mice (8-10 weeks old, 24 g) |
| Dosage: |
20; 60 mg/kg |
| Administration: |
p.o.; daily; 4 days |
| Result: |
Improved LPS-induced alterations in open field metrics including increased distance covered, distance in center, time in center, and activity time, alongside decreased time in corner and rest time. Reduced the number of Iba1+CD86+ pro-inflammatory microglia/macrophages in the cerebral cortex. Suppressed cerebral cortex levels of pro-inflammatory markers TNF-α, IL-1β, CD86, iNOS, and COX-2, while increasing anti-inflammatory markers IL-4, IL-10, and CD206 at 20 mg/kg dose. Produced similar, more pronounced effects at 60 mg/kg dose, including significant suppression of FPR1 and NLRP3 protein expression in the cerebral cortex. |
| Animal Model: |
Adult male Kunming mice (8-10 weeks old, 24 g) tMCAO model |
| Dosage: |
20; 60 mg/kg |
| Administration: |
i.g.; at 1, 24, and 48 hours post-I/R |
| Result: |
Reduced cerebral infarction volume in a dose-dependent manner, with the 60 mg/kg dose producing a larger reduction. Improved neurological function significantly, as shown by lower Longa scores, reduced rightward turning tendency in the corner test, and increased use of the affected forelimb in the cylinder test. Decreased the number of Iba1+CD86+ pro-inflammatory microglia/macrophages in the infarct-surrounding cerebral cortex, suppressed pro-inflammatory markers TNF-α, IL-1β, CD86, iNOS, and COX-2, and increased anti-inflammatory markers IL-4, IL-10, and CD206. Significantly reduced FPR1 and NLRP3 protein expression in the cerebral cortex at 60 mg/kg dose. |
| Animal Model: |
Male C57BL/6J ( 8-week-old) with hyperuricemic nephropathy induced by hypoxanthine and potassium oxonate |
| Dosage: |
20, 40, 80 mg/kg |
| Administration: |
i.g.; daily; 3 weeks |
| Result: |
Reduced elevated serum uric acid levels and liver xanthine oxidase (XOD) activity. Lowered kidney index, serum creatinine, blood urea nitrogen, and 24-hour albuminuria. Ameliorated renal histological damage. Dose-dependently reduced macrophage infiltration (F4/80-positive staining) and downregulated mRNA/protein expression of inflammatory markers (F4/80, Icam-1, IL-6, Ccl2, Nlrp3, IL-1b, MCP-1, NLRP3, IL-1β). Decreased renal collagen deposition and downregulated fibrosis markers (Fn1, Col4a1, Tgfb1, Timp1, FN, α-SMA) while increasing E-cadherin. Reversed dysregulation of renal uric acid transporters (upregulated Abcg2, Oat3, Oct2 mRNA and OAT1 protein. Downregulated Glut9 mRNA and URAT1, GLUT9 protein. Inhibited TLR4/NF-κB signaling. |
|